Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00110877 · ClinicalTrials.gov registry record · Phase 3
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
A Phase 3 study, sponsored by Tibotec Pharmaceuticals, Ireland.
- Completed
- Registry status
- Phase 3
- Development phase
- 604
- Enrollment target
NCT00110877 is a Phase 3 study that has completed, run by Tibotec Pharmaceuticals, Ireland. The registered enrollment target is 604 participants.
The verdict
NCT00110877, a Phase 3 study, has completed, sponsored by Tibotec Pharmaceuticals, Ireland.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 604 participants
- Enrollment target
Study Summary
Study TMC114-C214 is a randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114 boosted with low dose ritonavir (RTV) versus Kaletra (LPV)/RTV in lopinavir-naïve treatment-experienced HIV-1 infected patients.
Interventions
- DRUG LPV/rtv
- DRUG TMC114/rtv
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 604 participants |
| Start Date | 2005-04 |
| Est. Completion | 2011-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00110877
The ClinicalTrials.gov registry entry for NCT00110877 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 604 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tibotec Pharmaceuticals, Ireland, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which LPV/rtv is the first listed.
NCT00110877 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00110877 about?
NCT00110877 is a clinical study titled "TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients". Study TMC114-C214 is a randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114 boosted with low dose ritonavir (RTV) versus Kaletra (LPV)/RTV in lopinavir-naïve treatment-experienced HIV-1 infected patients.
What is the current status of trial NCT00110877?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 604 participants. The study started on 2005-04. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00110877?
The interventions under investigation include: LPV/rtv (DRUG), TMC114/rtv (DRUG).
Who is sponsoring clinical trial NCT00110877?
This trial is sponsored by Tibotec Pharmaceuticals, Ireland, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.